title: Adequate but not supplemental folic acid combined with soy isoflavones during early life improves bone health at adulthood in male mice.
abstract: Previous investigations from our laboratory have demonstrated that neonatal exposure to soy isoflavones (ISO) improves bone outcomes in CD-1 mice at adulthood with greater benefits in females than males. This study determined whether early-life exposure to supplemental folic acid (FA) - that may enhance DNA methylation of target genes - in combination with ISO provides greater benefits to male bone development than ISO alone. CD-1 dams were randomized to a low (0 mg/kg diet), adequate (2 mg/kg diet) or supplemental (8 mg/kg diet) level of FA during pregnancy and lactation. Offspring received corn oil or ISO (7 mg/kg of body weight per day) from postnatal day 1-10. From weaning, males were fed adequate FA and studied to age 4 months. Offspring exposed to adequate FA+ISO had multiple benefits to bone health: higher (P<.05) bone mineral density (BMD) and greater (P<.05) resistance to fracture at the femur and lumbar spine than mice exposed to adequate FA alone. Exposure to supplemental FA+ISO resulted in higher (P<.05) serum osteoprotegerin (OPG), and a higher ratio of OPG to receptor activator for nuclear factor κβ ligand (RANKL) but did not result in greater BMD or strength at the femur or lumbar spine than supplemental FA alone. In conclusion, early-life exposure to adequate FA+ISO provided functional benefits to male bone development, while improvements induced by supplemental FA+ISO were limited to a higher level of serum OPG. Mechanistic studies are needed to better understand how FA and ISO improve bone development in male offspring.
authors: Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada M5S 3E2.
authors: Jovana
authors: J
authors: Kaludjerovic
authors: Wendy E
authors: WE
authors: Ward
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005269:Femur / Q000502:physiology; D005492:Folic Acid / Q000008:administration & dosage*; D007529:Isoflavones / Q000494:pharmacology*; D008297:Male; D051379:Mice; D053244:Osteoprotegerin; D011247:Pregnancy; D053245:RANK Ligand / Q000378:metabolism; D013025:Glycine max / Q000737:chemistry
chemical_list: D007529:Isoflavones; D053244:Osteoprotegerin; D053245:RANK Ligand; C505689:Tnfsf11 protein, mouse; D005492:Folic Acid
keywords: Bone development; Folic acid; Male CD-1 mice; Soy isoflavones